 | |
| Clinical data | |
|---|---|
| MedlinePlus | a603033 |
| Routes of administration | Oral [1] |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.016.212 |
| Chemical and physical data | |
| Formula | C18H12AlN3O6 |
| Molar mass | 393.291 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Aluminium nicotinate is a niacin derivative used as a hypolipidemic agent.
The Merck Index is an encyclopedia of chemicals, drugs and biologicals with over 10,000 monograph on single substances or groups of related compounds published online by the Royal Society of Chemistry.
The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and present in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies in the world.
Schering-Plough Corporation was an American pharmaceutical company. It was originally the U.S. subsidiary of the German company Schering AG, which was founded in 1851 by Ernst Christian Friedrich Schering. As a result of nationalization, it became an independent company. In 1971, the Schering Corporation merged with Plough to form Schering-Plough. On November 4, 2009 Merck & Co. merged with Schering-Plough with the new company taking the name of Merck & Co.
Rofecoxib is a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). It was marketed by Merck & Co. to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, acute pain conditions, migraine, and dysmenorrhea. Rofecoxib was approved in the US by the US Food and Drug Administration (FDA) in May 1999, and was marketed under the brand names Vioxx, Ceoxx, and Ceeoxx. Rofecoxib was available by prescription in both tablet-form and as an oral suspension.
The Merck Manual of Diagnosis and Therapy, referred to as The Merck Manual, is the world's best-selling medical textbook, and the oldest continuously published English language medical textbook. First published in 1899, the current print edition of the book, the 20th Edition, was published in 2018. In 2014, Merck decided to move The Merck Manual to digital-only, online publication, available in both professional and consumer versions; this decision was reversed in 2017, with the publication of the 20th edition the following year. The Merck Manual of Diagnosis and Therapy is one of several medical textbooks, collectively known as The Merck Manuals, which are published by Merck Publishing, a subsidiary of the pharmaceutical company Merck Co., Inc. in the United States and Canada, and MSD in other countries in the world. Merck also formerly published The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals.
Felodipine is a medication of the calcium channel blocker type that is used to treat high blood pressure.
Sigma-Aldrich is an American chemical, life science, and biotechnology company owned by the multinational chemical conglomerate Merck Group.
2,2,2-Trichloroethanol is the chemical compound with formula Cl3C−CH2OH. Its molecule can be described as that of ethanol, with the three hydrogen atoms at position 2 replaced by chlorine atoms. It is a clear flammable liquid at room temperature, colorless when pure but often with a light yellow color.
Max Tishler (October 30, 1906 – March 18, 1989) was president of Merck Sharp and Dohme Research Laboratories where he led the research teams that synthesized ascorbic acid, riboflavin, cortisone, pyridoxine, pantothenic acid, nicotinamide, methionine, threonine, and tryptophan. He also developed the fermentation processes for actinomycin, vitamin B12, streptomycin, and penicillin. Tishler invented sulfaquinoxaline for the treatment for coccidiosis.
Karl August Folkers was an American biochemist who made major contributions to the isolation and identification of bioactive natural products.
Ditazole is a non-steroidal anti-inflammatory agent with analgesic and antipyretic activity similar to phenylbutazone. It is also a platelet aggregation inhibitor which is marketed in Spain and Portugal under the trade name Ageroplas.
Vorapaxar is a thrombin receptor antagonist based on the natural product himbacine, discovered by Schering-Plough and developed by Merck & Co.
DOV 216,303 is an experimental antidepressant drug originally developed by DOV Pharmaceutical and was licensed to Merck & Co. in 2004; Merck and DOV terminated their relationship in December 2006.
Tetronal is a sedative-hypnotic and anesthetic drug with GABAergic actions. It is not as effective as trional.
Fenpentadiol (INN), also known as phenpentanediol, is a drug described as a tranquilizer and antidepressant that was formerly marketed in Europe. It also has stimulant, sedative, and anxiolytic effects, with the latter two occurring only at higher doses.
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.
A pre-existing disease in pregnancy is a disease that is not directly caused by the pregnancy, in contrast to various complications of pregnancy, but which may become worse or be a potential risk to the pregnancy. A major component of this risk can result from necessary use of drugs in pregnancy to manage the disease.
Omarigliptin (MK-3102) is a potent, long-acting oral antidiabetic drug of the DPP-4 inhibitor class used for once-weekly treatment of type 2 diabetes and currently under development by Merck & Co. It inhibits DPP-4 to increase incretin levels, which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying and decreases blood glucose levels.
William Cecil Campbell is an Irish biologist and parasitologist with United States citizenship, known for his work in discovering a novel therapy against infections caused by roundworms, for which he was jointly awarded the 2015 Nobel Prize in Physiology or Medicine. He helped to discover a class of drugs called avermectins, whose derivatives have been shown to have "extraordinary efficacy" in treating River blindness and Lymphatic filariasis, among other parasitic diseases affecting animals and humans. Campbell worked at the Merck Institute for Therapeutic Research 1957–1990, and is currently a research fellow emeritus at Drew University.
Regrelor is an experimental antiplatelet drug that was under investigation by Merck Sharp and Dohme in human clinical trials. Although it was initially found to be well tolerated in healthy subjects, safety concerns led to cessation of clinical trials.
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
